Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (7)	4/11/1999 1:29:00 AM
From: Annointed1	Read Replies (1) \| Respond to of 226

You all might want to keep an eye on Boston Life Science (BLSI). Very strong research on antiangiogensis. They've recently been written up in a scientific journal discussing Troponin, their drug. They also just cleared Phase II with Altropane, a diagnostic drug for the earlier identification of Parkinson's. Rumor on the Yahoo board recently that they are imminently about to announce a partnership with a major drug company.

To: scaram(o)uche who wrote (7)	4/11/1999 11:50:00 PM
From: Rollcast...	Read Replies (2) \| Respond to of 226

Mike and Richard, have you reviewed that PR from NLAB (previous). Presenting at AACR with what they say is an FTI with 300 HUMAN tests to back up their assertion. Told they will be at ASCO as well. Frankly - most of this biotech stuff reads like gibberish to me but that seems like a fairly significant advance. If they have what they say they have with HUMAN clinical data backing it up. Checked out management and they are for real. The lead guy (Williams)was head of Oncology at N'western University and N'western Memorial as well.... heavily published, magna cum laude Yale, PHD from Harvard etc... There are some flags (non reporting, BB, etc...) but perhaps much more going for it than not going for it. What do you think? Are there any flags in the scientific assertions (the gibberish)? thx in advance ps: Mike, great idea for a thread.